ASXQuarterly Activities/Appendix 4C Cash Flow Report
other announcement
ANR
Pharmaceuticals, Biotechnology & Life Sciences
Anatara Lifesciences
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 14 Oct 2024
- Reported shorts
- 558
- Shares on issue
- 192.894M
Anatara Lifesciences (ANR) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Date of 2026 Annual General Meeting
other announcement
Anatara receives $318,402 in R&D Tax Incentive for FY26
other announcement
KalkineWhat Could Keep Anatara Lifesciences (ASX:ANR) in Focus Among Cannabis Stocks?
Highlights Anatara Lifesciences lodged its annual financial report for the year to the end of June The filing came days before notices covering new shares and a conversion of performance rights The group's platform traces back to a plant-derived compound drawn from pineapple stems Anatara Lifesciences Limited (ASX:ANR) has lodged its annual financial report for the year to the end of June, a filing that comes against a broader [All Ordinaries] trading mixed, days ahead of separate notices cov...
Conversion of Performance Rights and Cleansing Notice
other announcement
Google NewsAnatara Lifesciences Ltd (ASX:ANR) Share Price Remains Unchanged as Stock Trades at $0.009 - Kalkine
Anatara Lifesciences Ltd (ASX:ANR) Share Price Remains Unchanged as Stock Trades at $0.009 Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Change of Director Interest Notices x 3
director_dealing announcement
Anatara receives firm commitments for $1.2m Placement
capital_raise announcement
Anatara Annual General Meeting & Director Nominations
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Anatara receives $969,455 in R&D Tax Incentive for FY25
other announcement
Phase II GaRP-IBS Trial Internal Analyses of Data Subsets
other announcement
Phase II GaRP-IBS Trial Headline Analysis of Results
other announcement
Phase II GaRP-IBS Trial & Anti-Obesity Project Updates
other announcement